Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation  by Diamond, Jonathan R. & Karnovsky, Morris J.
Kidney International, Vol. 32 (1987), pp. 671—677
Exacerbation of chronic aminonucleoside nephrosis by dietary
cholesterol supplementation
JONATHAN R. DIAMOND and MORRIS J. KARNOVSKY
Department of Pathology, Harvard Medical School, and the Nephrology Section, Department of Medicine, New England Deaconess
Hospital, Boston, Massachusetts 02115, USA
Exacerbation of chronic aminonucleoside nephrosis by dietary choles-
terol supplementation. Abnormalities in lipid metabolism resulting from
nephrotic syndrome may play a role in the progression of initial
glomerular injury to focal and segmental glomerulosclerosis (FSGS). In
order to more specifically assess this, we fed male Sprague—Dawley
rats, made nephrotic with a single intravenous injection of puromycin
aminonucleoside (PA), either normal rodent chow (Group 1) or the
same formulation supplemented with 4% cholesterol/1% cholic acid
(Group 2). This 4% cholesterol/l% cholic acid—added diet was utilized
because, in normal, non-nephrotic rats, this alimentary supplement
produces, for the most part, only a significant rise in fasting serum
cholesterol and not fasting serum triglycerides. FSGS developed 18
weeks after PA delivery, and both groups of rats were studied func-
tionally and morphologically. Group 2 rats had significantly higher daily
urine protein excretion, lower inulin clearance, and greater blood urea
nitrogen concentrations than Group I animals. Histologically, Group 2
animals demonstrated a significantly greater percentage of glomeruli
examined with segmental areas of glomerulosclerosis/hyalinosis, me-
sangia! cell proliferation, and mesangial "foam" cells. At 2, 4, 12, and
18 weeks after PA delivery, the fasting serum cholesterol was always
significantly greater in Group 2 rats, whereas in regards to fasting serum
triglycerides it was only significantly elevated in Group 2 rats at 4 and
12 weeks after PA administration.
One of the several theories explaining the progression to focal
and segmental glomeruloscierosis (FSGS) following initial gb-
merular injury, from a variety of etiologies, may be related to
abnormalities in lipid metabolism [1]. Hyperlipoproteinemia,
resulting from augmented permeability and its associated sys-
temic perturbations [2, 3], could theoretically cause: further
neutralization of anionic sites in the glomerular filter by low—
density lipoproteins (LDL); increased macromolecular flux of
filtered lipoproteins into the mesangium with resultant mesan-
gial cell (MC) proliferation and overproduction of matrix sub-
stance; and damage to the arteriolar endothelium which may
produce untoward hemodynamic and/or thrombotic sequelae
that could exacerbate renal injury and allow for progression [1].
Recently, we have been utilizing a chronic aminonucleoside
nephrosis model, in the rat, that leads to FSGS 18 weeks after
a single intravenous dose of puromycin aminonucleoside (PA),
in an attempt to elucidate the mechanism(s) responsible for the
Received for publication September 22, 1986
and in revised form February 24, 1987
© 1987 by the International Society of Nephrology
progressive nature of glomerular disease [4]. Grond, van Goor
and Elema [5] have shown that rats, developing FSGS after
receiving multiple subcutaneous (s.c.) injections of PA, dem-
onstrate lipid accumulation within the glomeruli and, in partic-
ular, extensive deposition of lipid in areas of glomerubosciero-
sis. The authors hypothesized that, in chronic aminonucleoside
nephrosis, the increased accumulation of lipids in MC may lead
to an overproduction of matrix substance with even further
entrapment of lipids and eventually sclerosis [5]. More recently,
it has been noted in several models of glomerular disease,
including chronic aminonucleoside nephrosis, that there was
segmental glomerular accumulation of macrophages, serum
proteins, and lipids, primarily cholesterol and cholesterol ester
that strikingly resemble the lesion of atherosclerosis [6]. Be-
cause of these findings and the many similarities between the
vascular smooth muscle cells (VSMC) and the glomerular MC
in terms of origin [7], contractility [8], and inhibition of growth
in response to exogenously administered heparin compounds
[9, 10], we wanted to assess the functional and histologic
sequelae of modulating chronic aminonucleoside nephrosis with
a 4% cholesterol/1% cholic acid—supplemented diet which pri-
marily raises the total serum cholesterol without affecting the
serum triglycerides (Diamond and Rogers, unpublished obser-
vations) This is in contrast to the preliminary studies by
Edwards et al. [11, 121 where both plasma triglycerides and
cholesterol were elevated in rats given PA intraperitoneally and
maintained on a sucrose—lard (SL) diet. In both of those studies
[11, 12] the increment in plasma triglycerides far outweighed the
elevation in plasma total cholesterol.
Methods
Animal studies
Male Sprague—Dawley rats (Charles River Breeding Labora-
tories, Wilmington, Massachusetts, USA) weighing 250 to 300 g
were used. Chronic aminonucleoside nephrosis was induced by
single intravenous injection of PA (Sigma Chemical Company,
St. Louis, Missouri, USA), 5 mg per 100 g body weight over five
minutes through a PE-50 cannula in the right internal jugular
vein as previously reported [4]. Animals were divided into two
groups. Group 1 rats (N = 7) were fed a standard diet (Rodent
Laboratory Chow No. 5001, Ralston—Purina Company, St.
Louis, Missouri, USA). Group 2 animals (N = 7) were begun on
the same diet, but supplemented with 4% cholesterol and 1%
cholic acid (Tekiad Diets, Madison, Wisconsin, USA), one day
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after PAN delivery. An additional group of normal weight—
matched, male Sprague—Dawley rats (N = 4) was begun on the
cholesterol—supplemented diet to serve as normal dietary con-
trols (Group 3). We observed that rats assigned to either diet
gained weight at the same rate and ingested equal quantities of
food that were allotted on a per—gram body weight basis.
Urine was collected, over a 24-hour period, in metabolic
cages prior to the administration of PA and at 14, 28, 84, and 126
days after drug delivery. Urine protein was quantitated using
the Lowry method [13]. Serum was obtained at the above time
intervals for determination of fasting total cholesterol, triglyc-
erides, and urea nitrogen. Fasting serum was also obtained from
normal, male weight—matched rats on both the standard and
cholesterol—supplemented diets to assess the effects of this
dietary manipulation on the serum lipid profile at different time
intervals throughout this eighteen week study. Awake—systolic
blood pressure, by the tail—cuff method [141, was measured at
28, 56, and 126 days after PA administration.
Renal clearance studies
The effect of dietary cholesterol supplementation in chronic
aminonucleoside nephrosis on renal hemodynamics was studied
by inulin and para-aminohippuric acid (PAH) clearance techni-
ques. Rats were anesthetized by an intraperitoneal injection of
sodium pentobarbital (30 mg per kg body weight) and placed on
a constant—temperature table at 37°C. Animals then received a
0.9% sodium chloride infusion (10 ml per kg body weight) over
thirty minutes to compensate for volume losses associated with
anesthesia and surgery. Via a left internal jugular venous
cannula, a 0.9% sodium chloride solution containing 4% inulin
(Sigma Chemical Company, St. Louis, Missouri, USA) and
0.2% PAH (Merck, Sharp, and Dohme, West Point, Pennsyl-
vania, USA) was administered by continuous infusion via a
syringe pump at 1.8 ml per hour. A sixty—minute equilibration
period was utilized in order to obtain constant plasma levels of
inulin and PAH. Urine was collected in pre-weighed tubes via a
left ureteral cannula (PE-lO tubing). Plasma samples were
collected at the mid-point of each clearance period, each lasting
twenty minutes. Inulin and PAH concentrations in plasma and
urine were determined by modifications of standard colorime-
tric techniques [15, 16].
Preparation for light ,nicroscopy
Animals were anesthetized with ether 126 days after PA
administration, and the kidneys were perfused, in vivo, via an
infrarenal aol-tic cannula. The perfusate solution consisted of a
0.1 M cacodylate buffer containing 5% sucrose (pH 7.4) for two
to three minutes followed by 2% glutaraldehyde. Both kidneys
were removed, sectioned coronally, and immersed in 2% glu-
taraldehyde in cacodylate buffer for an additional two hours.
After fixation, 1- to 2-mm cortical strips were prepared from
coronal sections and, along with midcoronal sections, were
rinsed for an additional two hours in 0.1 M cacodylate buffer
with 5% sucrose (pH 7.4), embedded in Epon, and prepared for
light microscopy. Sections, approximately one micron thick,
were stained with either 1% toluidine blue or periodic acid -
Schiff (PAS) reagent [17]. Midcoronal sections of the whole
kidney were treated with borohydride [18] and stained with the
PAS reagent. Additional tissue was frozen in precooled Freon
(—100°C) and cut in a cryostat at 3 m so that frozen sections
could be stained with oil red 0 (ORO) to detect lipid deposition
within the glomerulus. Tissue was examined and photographed
with a Leitz photomicroscope.
The extent of increase in mesangial "foam" cells, segmental
mesangial proliferative areas, and the presence of glomerulo-
sclerosis/hyalinosis were evaluated and scored. A "foam cell"
was defined as a mesangial cell nucleus surrounded by fat
vacuoles. Mesangial cellularity was assessed by counting the
number of nuclei in each mesangial region. Nuclear counts
greater than three per mesangial region were considered to be
representative of mesangial hypercellularity. Glomerulosclero-
sis was defined as loss of cellular elements from the glomerular
capillary tuft, collapse of capillary lumina, and folding of the
glomerulàr basement membrane (GBM) with entrapment of
amorphous material. Hyalinosis was defined as rounded or
crescent—shaped foci of strongly eosinophilic material on PAS
staining, usually subendothelial in location, which could occur
in the capillary tuft with or without the sclerotic changes.
Approximately three hundred glomeruli per animal were eval-
uated to assess the percent total number of glomeruli with
glornerulosclerosis. Between seventy—five and one hundred
glOmeruli on Epon—embedded sections were scored to assess
percent total number of glomeruli with mesangial hypercellular-
ity. The rationale for utilizing this method was to avoid poten-
tial distortion from semiquantitative scoring due to the segmen-
tal nature of the lesion.
Statistical analysis
Data were reported as the mean one SE. Results between
groups were compared by Student's t-test. A P value of less
than 0.05 was considered statistically significant.
Results
The results of 24-hour proteinuria, fasting serum cholesterol
and triglycerides, and awake—systolic blood pressure in Groups
I and 2, throughout the course of the investigation, are illus-
trated in Figure 1. The reason for the high level of urine protein
excretion as well as elevated cholesterol atid triglyceride values
at two weeks in both groups, compared with subsequent time
periods, is that this interval represents the peak nephrotic stage
following a single intravenous dose of PA [4]. Urine protein
excretion was not significantly different between the two groups
until 18 weeks after PA administration. At that time point,
Group 1 excreted a mean of 119.7 17.7 mg per 24 hours,
whereas Group 2 had a dramatic rise to a mean of 449.5 96.7
mg per 24 hours. During the entire study, the fasting serum
cholesterol value was always significantly different between the
two groups, being between three— and sixfold greater in the 4%
cholesterol/l% cholic acid—supplemented diet group as com-
pared to the standard diet group (P < 0.001). In regards to the
fasting serum triglyceride level, there was no significant differ-
ence betweeh the two groups at either 2 or 18 weeks after PA
delivery. However, fasting serum triglyceride levels were sig-
nificantly elevated in Group 2 animals at the four— and twelve—
week intervals. The values for awake—systolic blood pressure
were also not consistent throughout the course of the study in
that Group 2 animals had significant elevations from Group 1
values at the 4- and 18-week intervals, but not at the eight—week
time point. At all time intervals examined, there were no
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Fig. 1. Urine protein excretion (A), fasting serum cholesterol (B),
fasting serum triglycerides (C), and systolic blood pressure (D) in rats
with chronic aminonucleoside nephrosis fed a standard diet (l Group
1) compared to those maintained on a cholesterol supplemented diet (
Group 2) at selected time intervals after puromycin aminonucleoside
(PA) administration. Statistical significance between groups is denoted
above error bars.
differences in body weights or urine volumes between the two
groups.
In regards to the lipid profile of normal rats maintained on the
4% cholesterolll% cholic acid—supplemented diet (Group 3),
values for fasting serum cholesterol and fasting serum triglyc-
erides appear on Figure 2. Eighteen weeks after beginning the
cholesterol—supplemented diet, the fasting serum cholesterol
and triglycerides in normal rats were 244.7 42.7 mg/dl and
109.0 20.9 mg/dl, respectively. This is in contrast to the
corresponding levels of fasting serum cholesterol and fasting
serum triglycerides in normal rats maintained on standard
rodent chow at eighteen weeks being 31.7 1.5 mg/dl and 91.0
12.8 mg/dl, respectively. As is evident from the data in Figure
2, this experimental diet, in normal animals, produces a rise in
the fasting serum cholesterol (approximately an eightfold incre-
ment), at all time intervals measured, while the fasting serum
triglycerides are normal at the beginning and end of the study,
but for some, as yet, unclear reason(s), become nearly twice
normal at 12 weeks after commencement of the cholesterol—
supplemented diet. In addition, the values for awake systolic
blood pressure; and urine protein excretion, at the various time
intervals after starting the cholesterol—supplemented diet, in
Group 3 animals appear in Figure 2. The awake systolic blood
pressure for these normal cholesterol—supplemented dietary
controls was the same as for Groups 1 and 2. The urine protein
excretion in Group 3 animals followed a similar pattern for
normal Sprague—Dawley rats on a normal diet [41 and was
significantly less than proteinuria values for Group 2 animals
during the periods of acute nephrosis (2 and 4 weeks, P < 0.005)
and appearance of FSGS (18 weeks, P < 0.05).
Fig. 2. Urine protein excretion (A), fasting serum cholesterol (B),
fasting serum triglycerides (C), and systolic blood pressure (D) in rats
with chronic aminonucleoside nephrosis fed a cholesterol supple-
mnted diet (• Group 2) and normal rats fed the cholesterol supple-
ment (t Group 3) at selected time intervals. Statistical significance
between groups is denoted above error bars. Horizontal bars at all time
intervals denote mean values for normal rats fed standard rodent chow.
GFR RPF FF BUN
Group mI/mm mi/mm % mg/dl
Table 1 summarizes the renal functional data in Groups 1 and
2 at 18 weeks after PAN administration. The mean glomerular
filtration rate (GFR), determined by inulin clearance, was
significantly lower in Group 2 animals (1.54 0.12 ml/min
versus 1.13 0.14 ml/min, P < 0.05). The inulin clearance in
Group 3 animals was 1.77 0.08 mI/mm, which was signifi-
cantly greater than Group 2 rats (P < 0.02) but not different
from nephrotic rats maintained on the standard diet. Although
the renal plasma flow rate (RPF), determined by para-aminohi-
pppurate clearance, was numerically lower in the nephrotic
animals maintained on the 4% cholesterol/1% cholic acid sup-
plement, this difference did not reach statistical significance
when compared with Group 1 rats. The PAH clearance for
Table 1. Summary of functional data 18 weeks after puromycin
arninonucleoside
PA/standard diet 1.54 0.12 4.85 0.70 34.3 2.7 19.3 1.1
(N =7)
PA/4%
cholesterol 1.13 0.14 3.73 0.56 32.6 4.7 27.7 1.2
1% cholic acid
diet (N = 7)
P <0.05 NS NS <0.025
Abbreviations are: GFR, glomerular filtration rate; RPF, renal plas-
ma flow; FF, filtration fraction; BUN, blood urea nitrogen; NS, not
significant
Normal values are: GFR = 1.68 0.22mI/mm; RPF = 6.1 0.36 ml/
mm; FF = 27.6%; BUN = 16.0 1.1 mg/dl
674 Diwnond and Karnovsky
increased to 59,9 3.4 percent in animals fed the 4% choles-
terol/1% cholic acid supplement (P < 0.05). Similarly, the
percentage of glomeruli with the glomeruloscierosis/hyalinosis
lesions was significantly increased in Group 2 animals (28.9
2.1 versus 18.0 3.2 percent, P < 0.025). In normal animals
maintained on the cholesterol supplement, the percentage of
glomeruli with glomerulosclerosis/hyalinosis lesions was 1.6
0.3 percent. In Group 2 rats, the percent of glomeruli with
mesangial "foam" cells was also increased as compared to
nephrotic rats maintained on the standard diet (62.4 5.9
versus 16.6 2.4 percent, P < 0.001).
Discussion
Fig. 3. Representative glomerulus from a cholesterol—supplemented
animal 18 weeks after PA administration. The black arrowheads show
segmental areas of capillary collapse with accumulation of amorphous,
hyaline.-like material (Toluidine blue, x390).
normal rats fed the cholesterol supplement was 5.74 0.58
ml/min which was statistically indifferent from either Groups 1
or 2. Likewise, filtration fractions were similar in all groups.
The blood urea nitrogen (BUN) value in Group 1 animals was a
mean of 19.3 1.1 mg/dl and was significantly elevated to a
mean of 27.7 1.2 mg/dl (P < 0.025) in Group 2 rats.
Renal histopathology was evaluated in both groups by light
microscopy and with special stains. Representative histologic
sections of the glomerular abnormalities that were quantita-
tively assessed are shown in Figures 3, 4, and 5. In Figure 3,
there is a representative glomerulus stained with toluidine blue.
The mesangium is markedly expanded and contains hyper-
cellular areas of MC, many of which are vacuolated with lipid
droplets (that is, "foam" cells). In addition, there are segmental
areas of capillary collapse and visceral epithelial cell injury, as
evidenced by the presence of cytoplasmic blebs, in the periph-
eral capillary loops. Figure 4 demonstrates representative gb-
meruli from tissue embedded in paraffin, sectioned at approxi-
mately 5 m, and stained with PAS and revealing the segmental
glomeruloscierosis/hyalinosis lesion. These lesions occurred in
both the outer cortical and juxtamedullary areas. However, in
contrast to the renal ablation model [19], there were no areas of
extensive hyalinosis or global glomerulosclerosis found at the
end of the 18 week period. Similarly, there was no histologic
evidence of hypertensive damage in the renal vasculature in
either group. Figure 5 confirms the segmental deposition of lipid
within the mesangium on ORO staining of frozen sections.
These areas would correspond to those that, on toluidine blue
staining, manifested "foam" cells and an expanded mesangium
containing amorphous debris.
The effect of dietary supplementation with cholesterol and
cholic acid on the above—mentioned morphological abnormali-
ties 126 days after PA administration is shown in Table 2. Group
1 rats, at sacrifice, had 44.2 5.7 percent of glomeruli exam-
ined demonstrating segmental areas of MC proliferation. The
percentage of these areas in glomeruli scored was significantly
Dramatic changes in the serum profile of total cholesterol,
triglycerides, and phospholipids occur as a consequence of the
nephrotic syndrome. Gheradi et al [20], have shown that
very—low—density ljpoprotein (VLDL) and low—density lipopro-
tein (LDL) are increased in nephrotic patients, while high—dens-
ity lipoproteins (HDL), on the other hand, may be normal or
low. Although it has been simply stated that increased concen-
trations of lipoproteins could be the result of either increased
lipoprotein synthesis or decreased lipoprotein catabolism by
peripheral tissues [21], some elaborate mechanisms have been
postulated. De Mendoza et al [2], have shown that the urine
from nephrotic rats 7 and 18 days after PA injection contained
a powerful activator effect when added to an in vitro lipoprotein
lipase system. The lipoprotein lipase activator property has
been shown to be a component of HDL and functions in the
clearance of plasma triglycerides [22]. There is speculation that,
since the molecular weight of HDL is the lowest of all the
classes of lipoproteins, it might be that HDL would be lost
preferentially into the urine, with its lipoprotein lipase—activat-
ing potential, more than LDL or VLDL [2] thereby contributing
to the hyperlipidemia following glomerular injury. Along other
pathophysiologic lines, Appel Ct al [3] have recently shown that
a significant inverse correlation exists between the total plasma
cholesterol concentration and both the plasma albumin concen-
tration and plasma oncotic pressure.
It had been previously demonstrated by French, Yamanaka
and Ostwald [23] that a 1% cholesterol diet given to guinea pigs
made anemic resulted in glornerulosclerosis. This present study
attempted to define whether alimentary hypercholesterolemia,
superimposed on the hyperlipidemia of aminonucleoside ne-
phrosis, could exacerbate the underlying renal disorder. The
data demonstrate that chronic arninonucleoside nephrosis can
be further aggravated, both functionally and histologically, by a
dietary manipulation with 4% cholesterolll% cholic acid sup-
plement that preferentially raises the fasting serum cholesterol
and not the triglyceride level in normal rats. This is in sharp
contrast to the preliminary observations of Edwards et al [11,
12] who have also shown an exacerbation of chronic aminonu-
cleoside nephrosis by dietary modulation with a sucrose—lard
(SL) diet; however, that maneuver raised both the plasma
triglyceride and total cholesterol levels, with the former clearly
comprising the predominant elevation [11, 12].
The mechanism for this decline in renal function and the
increased severity of the glomerular morphologic abnormalities
18 weeKs after PA delivery, in our model, is not entirely clear,
but our results reveal a very significant difference in the fasting
serum cholesterol level at all the time points examined, while
-"I
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Fig. 4. Representative glomeruli from a
cholesterol—supplemented animal 18 weeks
after PA administration. Black arrows show
extensive segmental areas of
glomeruloscierosis. The smaller white arrows
indicate subendothelial, crescent-shaped
accumulations of hyaline material (Periodic
acid-Schiff, x300).
Fig. 5. Two representative glomeruli from a
cholesterol—supplemented animal 18 weeks
after PA administration. Black arrowheads
indicate segmental mesangial areas of intense
lipid deposition as identified by Oil Red 0
staining (x350).
Table 2. Summary of morphologic abnormalities 18 weeks after
puromycin aminonucleoside
Percent
glomeruli
with gb-
Percent gbomeruli merulos-
Percent glomeruli with segmental clerosis/
with mesangial mesangial prolif- hyalinosis
Groups "foam" cells erative areas lesions
PA/standard diet 16.6 2.4 44.2 5.7 18.0 3.2
(N = 7)
PA/4%
cholesterol!
1% cholic acid 62.4 5.9 59.9 3.4 28.9 2.1
(N = 7)
P <0.001 <0.05 <0.025
there were less consistent, albeit significant, differences in the
fasting serum triglyceride level and awake—systolic blood pres-
sure at different time intervals during the course of this inves-
tigation. The observation of a preferentially elevated, fasting
serum cholesterol—level in normal rats on the 4% cholesterol!
1% cholic acid—supplemented diet, coupled with only the fast-
ing serum cholesterol being consistently significantly elevated
at all time intervals examined in nephrotic rats on the choles-
terol-supplemented diet, suggests that alimentary hypercholes-
terolemia may play an important role in the progression of
initial toxic glomerular injury by PA to FSGS. This hypothesis
is further supported by data from Edwards et al [1 lb in which
rats with aminonucleoside nephrosis fed the SL diet but also
treated with 1% dietary tryptophan had significant lowering of
proteinuria and the blood urea nitrogen (BUN). Interestingly,
these rats exhibiting protection by the dietary L-tryptophan
supplement demonstrated only a significant fall in plasma total
cholesterol (231 mg!dl to 151 mg!dl), whereas the plasma triglyce-
ride level did not fall significantly (681 mg/dl to 552 mg!dl).
Interestingly, Clowes et al [24] have demonstrated that lipo-
protein electrophoresis of sera from rats fed this same dietary
cholesterol supplement reveals a very prominent beta—band as
compared to normal diet controls. This lipoprotein had a
cholesterol—to—triglyceride ratio of approximately 60:1. Las sler
et al [25] noted in rats fed a similar cholesterol—supplemented
diet that the serum VLDL concentration was very high and that
the composition of this lipoprotein was different from that of
normal animals in its disproportionate increase in cholesterol
content.
Moorhead, Chan and Varghese [211 have postulated three
mechanisms by which hyperlipoproteinuria, resulting from initial
glomerular injury, could cause progressive renal damage and
glomerulosclerosis. At physiologic pH, the cationic sites of
VLDL and LDL could conceivably bind with glycosaminoglycans
(such as, heparan sulfate) [211 and thereby further neutralize
additional anionic moieties which determine the charge—selec-
tive characteristic of the glomerular barrier, with the net result
being an increase in glomerular permeability. A second mech-
anism is centered on the accumulation of filtered lipoprotein in
676 Diamond and Karnovsky
mesangial cells. This increased macromolecular flux into the
mesangium could stimulate the mesangial cells to proliferate
and produce excess basement membrane material [1], both of
which appear to be pathologic harbingers of glomerulosclerosis
[26]. Further support for this theory rests in data derived from
tissue culture experiments with VSMC, which bear striking
similarities with the glomerular mesangial cell in terms of origin
[71, contractility [8], and growth regulators [9, 10]. It has been
demonstrated in VSMC in vitro [27], that serum from animals
with alimentary hyperlipidemia has a stimulative effect on cell
proliferation. This finding suggests that exposure in vivo to
hypercholesterolemia induced by cholesterol feeding may actu-
ally increase the growth potential of VSMC in vitro. The exact
nature of what the growth—promoting factor(s) of hyperlipemic
serum remains unknown, but the analogy may be applicable to
the glomerular mesangial cell. Alternatively, it is also possible
that the mesangial hypercellularity results from infiltrating
macrophages into the mesangium, since Schreiner, Cotran and
Unanue [28] have demonstrated Ia-positive cells in aminonu-
cleoside nephrosis. A third potential mechanism for self—perpe-
tuating glomerular injury is damage to the endothelial lining of
arterioles by the hyperlipidemia resulting from the nephrotic
syndrome [21]. Endothelial cells incubated with LDL are dam-
aged, as evidenced by increased 51chromium release, but are
protected by adding HDL and albumin [29]. In nephrotic
animals, the combination of an elevated LDL coupled with low
HDL and/or albumin levels could expose endothelial cells to the
toxic effects of LDL [211. Endothelial cell damage induced by
LDL might even compromise the celfs' ability to produce
vasoactive substances (such as prostacyclin) which may result
in untoward hemodynamic or thrombotic consequences and
subsequent glomerular injury [211.
The observation of significant increments in awake—systolic
blood pressure at 4 and 18 weeks after PA delivery in Group 2
rats warrants some comment. We have previously shown that
chronic aminonucleoside nephrosis in the Sprague—Dawley rat
is not accompanied by elevations in awake—systolic blood
pressure [30]. It could be that either the hyperlipidemia result-
ing from both the dietary manipulation and the nephrotic
syndrome contributed to a generalized arteriosclerotic process
accompanied by an elevated systolic blood pressure or that the
augmented systolic blood pressure resulted from more pro-
found renal disease produced by the alimentary hypercholeste-
rolemia. Although the presence of an increased awake—systolic
blood pressure at four weeks, which is a time point that lacks
the signs of glomerulosclerosis, argues for the former scenario,
the absence of histologic evidence for generalized arterioscle-
rosis or significant hypertensive damage make it less likely that
the elevated awake—systolic blood pressure contributed to the
aggravated renal disease as an isolated variable. One may then
have to view the elevated systolic blood pressure as only a
contributing feature to the exacerbation of the renal disease and
not the primary determinant. Interestingly, Edwards [311 re-
ported that hydralazine conferred renal protection while lower-
ing not only the moderately—elevated blood pressure in SL-fed,
spontaneously hypertensive rats (SHR) with chronic aminonu-
cleoside nephrosis, but also the elevated plasma, total choles-
terol level. This antihypertensive agent, however, did not
reduce the plasma triglycerides in the same SL-fed SHR with
the amelioration of chronic aminonucleoside nephrosis.
Our data, coupled with these additional observations in
chronic aminonucleoside nephrosis, suggest that alimentary
hypercholesterolemia with or without a synergistic effect from
an elevated, systolic blood pressure may contribute to the
exacerbation of the abnormal glomerular morphology and func-
tion in this experimental model of nephrotic syndrome. Al-
though it remains possible, we feel that these findings do not
support as strongly a significant role for dietary hypertriglyce-
ridemia in the aggravation of chronic aminonucleoside nephrosis
by institution of a 4% cholesterol/l% cholic acid—supplemented
diet, despite the observed significant increments in fasting hyper-
triglyceridemia at 4 and 12 weeks after PA administration in
Group 2 animals. In addition, the near doubling of fasting,
serum triglyceride levels at 12 weeks after commencing the
cholesterol—supplemented diet in normal dietary controls does
raise the possibility that the episodic hypertriglyceredemia is
related to extraneous metabolic effects from consuming this diet
for a protracted period of time.
Clearly, additional in vivo investigations need to be con-
ducted in order to assess whether agents that preferentially
lower serum cholesterol (such as cholestyramine) confer pro-
tection in this model and whether they are superior to drugs that
primarily modify serum triglycerides. Also, studies are pres-
ently underway to evaluate the effect of sera from animals with
alimentary hypercholesterolemia, with and without the super-
imposition of aminonucleoside nephrosis, on MC growth and
function, in vitro.
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